Incidental Pituitary FDG Uptake on PET‐CT: A Retrospective Review of Current Practice and Outcomes at a UK Tertiary Centre
Clinical Endocrinology · 2025
DOI: 10.1111/cen.70060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Trevor Tam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Norfolk and Norwich University Hospital, Norwich, Norfolk, UK. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Pituitary Gland. Die Arbeit nennt 35 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Context
Fluorine‐18 fluorodeoxyglucose (FDG) positron emission tomography‐computed tomography (PET‐CT) is widely used in malignancy diagnosis and surveillance. However, benign conditions also increase avidity. Distinguishing between benign and pathological uptake is critical. Rising PET‐CT utilisation has led to increased detection of incidental pituitary FDG uptake. Referral pathways and secondary imaging remain inconsistent, and no UK guidelines exist. This study aims to review our current practice and assess the potential role of SUVmax to differentiate physiological from pathological uptake in the pituitary gland.
Design
A retrospective single‐centre cohort study was conducted at a UK tertiary hospital. Patients Among 15824 PET‐CT scans between 01/01/2017–30/06/2024, 70 patients (mean age 72.1 ± 1.3 years, 25.7% female) were included.
Measurements
Demographics, primary pathology, oncological treatment, SUVmax on initial PET‐CT, secondary imaging findings, endocrine referral, and pituitary biochemistry were collected.
Results
48 patients (68.6%) underwent secondary imaging; 70.8% ( n = 34) were normal. Pathological findings included macroadenomas ( n = 6), microadenomas ( n = 3), and other lesions ( n = 5). Mean SUVmax was significantly higher in patients with pituitary pathology (pituitary adenomas‐ 20.62 ± 4.82; all pathology‐ 16.74 ± 3.80) versus normal imaging‐ 4.66 ± 0.26 ( p < 0.001). A SUVmax threshold of 4.75 yielded 100% sensitivity and 53.9% specificity for detecting pituitary pathology (ROC curve; 95% CI: 69%–100%).
Conclusions
Our review highlights significant variation in referral patterns for secondary imaging and to the Endocrine department. We suggest potential use of SUVmax threshold to distinguish physiological from pathological pituitary FDG uptake. Further validation in larger cohorts is warranted before routine clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Norfolk and Norwich University Hospital, Norwich, Norfolk, UK.
- University of East Anglia, Norwich, Norfolk, UK.
- Cambridge University Hospitals, Cambridge, UK.
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Tam, T., Naing, T. K. P., Elzubeir, L., Swords, F., Dhatariya, K., Barbara, R. R., & Ahluwalia, R. (2025). Incidental Pituitary FDG Uptake on PET‐CT: A Retrospective Review of Current Practice and Outcomes at a UK Tertiary Centre. Clinical Endocrinology. https://doi.org/10.1111/cen.70060
Vancouver
Tam T, Naing TKP, Elzubeir L, Swords F, Dhatariya K, Barbara RR, et al. Incidental Pituitary FDG Uptake on PET‐CT: A Retrospective Review of Current Practice and Outcomes at a UK Tertiary Centre. Clinical Endocrinology. 2025. doi:10.1111/cen.70060
BibTeX
@article{Tam2025,
author = {Tam, Trevor and Naing, Thin Kyi Phyu and Elzubeir, Lee and Swords, Francesca and Dhatariya, Ketan and Barbara, Ramona-Rita and Ahluwalia, Rupa},
title = {Incidental Pituitary FDG Uptake on PET‐CT: A Retrospective Review of Current Practice and Outcomes at a UK Tertiary Centre},
journal = {Clinical Endocrinology},
year = {2025},
doi = {10.1111/cen.70060}
}
EUVIMED